Delgocitinib Demonstrates Dose–Response in Chronic Hand Eczema
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose-response in chronic hand eczema in a 16-week randomised phase 2b trial
Br J Dermatol 2022 Jan 27;[EPub Ahead of Print], M Worm, JP Thyssen, S Schliemann, A Bauer, VY Shi, B Ehst, S Tillmann, S Korn, K Resen, T AgnerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.